NCT03915223

Brief Summary

The assessment consists in comparing corticoids injection versus placebo in surgery of lower limb fractures The aim of study is to assess (state cutaneous, efficacy, safety) corticoids injection on a prospective, randomized analysis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 4, 2019

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 16, 2019

Completed
24 days until next milestone

Study Start

First participant enrolled

May 10, 2019

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 25, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2024

Completed
Last Updated

May 8, 2024

Status Verified

May 1, 2024

Enrollment Period

4.6 years

First QC Date

April 4, 2019

Last Update Submit

May 7, 2024

Conditions

Keywords

preoperative procedureleg fracturesosteosynthesiscorticosteroids

Outcome Measures

Primary Outcomes (1)

  • leg perimeter

    measure of leg perimeter at the fractured area compared to the contralateral side

    2 days

Secondary Outcomes (13)

  • leg perimeter

    15 days

  • leg perimeter

    7 days

  • pain leg

    preoperative

  • pain leg

    2 days

  • pain leg

    7 days

  • +8 more secondary outcomes

Study Arms (2)

Arm "Injection corticosteroids"

EXPERIMENTAL

Single dose of Solumedrol 2 mg/kg

Procedure: leg fracture

Arm " injection physiological serum"

PLACEBO COMPARATOR

Single dose of physilogical serum

Procedure: leg fracture

Interventions

leg fracturePROCEDURE

Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum

Arm " injection physiological serum"Arm "Injection corticosteroids"

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient over the age of 18, hospitalized in the Orthopedics Department for a leg fracture (ankle, tibia: proximal, diaphysis, distal) requiring surgery within 72 hours of the trauma
  • Patient covered by the social security system
  • Patient giving informed consent

You may not qualify if:

  • Open fracture with infectious risks cauchoix 2 and 3
  • Multiple trauma,
  • Pathological fracture on primary or secondary lesions,
  • Pre-existing bone disease (excluding osteoporosis) of the operated limb,
  • Diabetes,
  • Pre-existing trophic disorders on one of the 2 lower limbs,
  • Long-term corticotherapy,
  • Pathology of the pituitary-adrenal axis,
  • Any other contraindication to glucocorticoids: any infectious condition, some developing viral diseases (including hepatitis, herpes, chicken pox, shingles), hypersensitivity to one of the constituents
  • Hypernatremia and hypochloremia
  • Pre-existing severe cardiac injury
  • Contraindication to TegadermTM
  • Patient placed under guardianship, tutorship or safeguard of justice,
  • Pregnant or lactating women,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, 63000, France

Location

MeSH Terms

Conditions

Leg InjuriesFractures, BoneEdema

Condition Hierarchy (Ancestors)

Wounds and InjuriesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Stéphane Boisgard

    University Hospital, Clermont-Ferrand

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
double blinded
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Solumedrol (steroidal anti-inflammatory drug) injection
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2019

First Posted

April 16, 2019

Study Start

May 10, 2019

Primary Completion

December 25, 2023

Study Completion

May 6, 2024

Last Updated

May 8, 2024

Record last verified: 2024-05

Locations